Philips provides update on performance and value creation journey at Capital Markets Day in Amsterdam

Amsterdam, the Netherlands – At a meeting with investors and financial analysts today in Amsterdam, Royal Philips (NYSE: PHG, AEX: PHIA) CEO Frans van Houten, together with CFO Abhijit Bhattacharya and several executives, will provide an update on the company’s performance and value creation journey.
“We are excited about the strong demand for our health technology innovations, and we will continue to drive our value creation journey, delivering mid-single-digit comparable sales growth and an annual improvement of the Adjusted EBITA margin of around 100 basis points,” said Frans van Houten. “To expand our market positions, increase margins and fully unlock Philips’ potential, we will further improve customer and operational excellence, boost growth in our core businesses through geographical expansion and consultative customer partnerships, and innovate with integrated solutions to improve people’s health and enhance the productivity of care providers.”

Innovation is core to Philips’ value creation, as exemplified by the company’s deep clinical partnerships and global EUR 1.8 billion R&D program. More than half of Philips’ annual sales is related to new product sales [3], such as Philips’ Azurion next-generation image-guided therapy platform, General Care Solution with Early Warning Scoring to identify subtle signs of deterioration in a general floor patient’s condition, and Dream Family solution for sleep therapy.

Amsterdam, the Netherlands – At a meeting with investors and financial analysts today in Amsterdam, Royal Philips (NYSE: PHG, AEX: PHIA) CEO Frans van Houten, together with CFO Abhijit Bhattacharya and several executives, will provide an update on the company’s performance and value creation journey.
“We are excited about the strong demand for our health technology innovations, and we will continue to drive our value creation journey, delivering mid-single-digit comparable sales growth and an annual improvement of the Adjusted EBITA margin of around 100 basis points,” said Frans van Houten. “To expand our market positions, increase margins and fully unlock Philips’ potential, we will further improve customer and operational excellence, boost growth in our core businesses through geographical expansion and consultative customer partnerships, and innovate with integrated solutions to improve people’s health and enhance the productivity of care providers.”

Innovation is core to Philips’ value creation, as exemplified by the company’s deep clinical partnerships and global EUR 1.8 billion R&D program. More than half of Philips’ annual sales is related to new product sales [3], such as Philips’ Azurion next-generation image-guided therapy platform, General Care Solution with Early Warning Scoring to identify subtle signs of deterioration in a general floor patient’s condition, and Dream Family solution for sleep therapy.

Amsterdam, the Netherlands – At a meeting with investors and financial analysts today in Amsterdam, Royal Philips (NYSE: PHG, AEX: PHIA) CEO Frans van Houten, together with CFO Abhijit Bhattacharya and several executives, will provide an update on the company’s performance and value creation journey.
“We are excited about the strong demand for our health technology innovations, and we will continue to drive our value creation journey, delivering mid-single-digit comparable sales growth and an annual improvement of the Adjusted EBITA margin of around 100 basis points,” said Frans van Houten. “To expand our market positions, increase margins and fully unlock Philips’ potential, we will further improve customer and operational excellence, boost growth in our core businesses through geographical expansion and consultative customer partnerships, and innovate with integrated solutions to improve people’s health and enhance the productivity of care providers.”

Innovation is core to Philips’ value creation, as exemplified by the company’s deep clinical partnerships and global EUR 1.8 billion R&D program. More than half of Philips’ annual sales is related to new product sales [3], such as Philips’ Azurion next-generation image-guided therapy platform, General Care Solution with Early Warning Scoring to identify subtle signs of deterioration in a general floor patient’s condition, and Dream Family solution for sleep therapy.

Amsterdam, the Netherlands – At a meeting with investors and financial analysts today in Amsterdam, Royal Philips (NYSE: PHG, AEX: PHIA) CEO Frans van Houten, together with CFO Abhijit Bhattacharya and several executives, will provide an update on the company’s performance and value creation journey.
“We are excited about the strong demand for our health technology innovations, and we will continue to drive our value creation journey, delivering mid-single-digit comparable sales growth and an annual improvement of the Adjusted EBITA margin of around 100 basis points,” said Frans van Houten. “To expand our market positions, increase margins and fully unlock Philips’ potential, we will further improve customer and operational excellence, boost growth in our core businesses through geographical expansion and consultative customer partnerships, and innovate with integrated solutions to improve people’s health and enhance the productivity of care providers.”

Innovation is core to Philips’ value creation, as exemplified by the company’s deep clinical partnerships and global EUR 1.8 billion R&D program. More than half of Philips’ annual sales is related to new product sales [3], such as Philips’ Azurion next-generation image-guided therapy platform, General Care Solution with Early Warning Scoring to identify subtle signs of deterioration in a general floor patient’s condition, and Dream Family solution for sleep therapy.

Amsterdam, the Netherlands – At a meeting with investors and financial analysts today in Amsterdam, Royal Philips (NYSE: PHG, AEX: PHIA) CEO Frans van Houten, together with CFO Abhijit Bhattacharya and several executives, will provide an update on the company’s performance and value creation journey.
“We are excited about the strong demand for our health technology innovations, and we will continue to drive our value creation journey, delivering mid-single-digit comparable sales growth and an annual improvement of the Adjusted EBITA margin of around 100 basis points,” said Frans van Houten. “To expand our market positions, increase margins and fully unlock Philips’ potential, we will further improve customer and operational excellence, boost growth in our core businesses through geographical expansion and consultative customer partnerships, and innovate with integrated solutions to improve people’s health and enhance the productivity of care providers.”

Innovation is core to Philips’ value creation, as exemplified by the company’s deep clinical partnerships and global EUR 1.8 billion R&D program. More than half of Philips’ annual sales is related to new product sales [3], such as Philips’ Azurion next-generation image-guided therapy platform, General Care Solution with Early Warning Scoring to identify subtle signs of deterioration in a general floor patient’s condition, and Dream Family solution for sleep therapy.

Amsterdam, the Netherlands – At a meeting with investors and financial analysts today in Amsterdam, Royal Philips (NYSE: PHG, AEX: PHIA) CEO Frans van Houten, together with CFO Abhijit Bhattacharya and several executives, will provide an update on the company’s performance and value creation journey.
“We are excited about the strong demand for our health technology innovations, and we will continue to drive our value creation journey, delivering mid-single-digit comparable sales growth and an annual improvement of the Adjusted EBITA margin of around 100 basis points,” said Frans van Houten. “To expand our market positions, increase margins and fully unlock Philips’ potential, we will further improve customer and operational excellence, boost growth in our core businesses through geographical expansion and consultative customer partnerships, and innovate with integrated solutions to improve people’s health and enhance the productivity of care providers.”

Innovation is core to Philips’ value creation, as exemplified by the company’s deep clinical partnerships and global EUR 1.8 billion R&D program. More than half of Philips’ annual sales is related to new product sales [3], such as Philips’ Azurion next-generation image-guided therapy platform, General Care Solution with Early Warning Scoring to identify subtle signs of deterioration in a general floor patient’s condition, and Dream Family solution for sleep therapy.

Amsterdam, the Netherlands – At a meeting with investors and financial analysts today in Amsterdam, Royal Philips (NYSE: PHG, AEX: PHIA) CEO Frans van Houten, together with CFO Abhijit Bhattacharya and several executives, will provide an update on the company’s performance and value creation journey.
“We are excited about the strong demand for our health technology innovations, and we will continue to drive our value creation journey, delivering mid-single-digit comparable sales growth and an annual improvement of the Adjusted EBITA margin of around 100 basis points,” said Frans van Houten. “To expand our market positions, increase margins and fully unlock Philips’ potential, we will further improve customer and operational excellence, boost growth in our core businesses through geographical expansion and consultative customer partnerships, and innovate with integrated solutions to improve people’s health and enhance the productivity of care providers.”

Innovation is core to Philips’ value creation, as exemplified by the company’s deep clinical partnerships and global EUR 1.8 billion R&D program. More than half of Philips’ annual sales is related to new product sales [3], such as Philips’ Azurion next-generation image-guided therapy platform, General Care Solution with Early Warning Scoring to identify subtle signs of deterioration in a general floor patient’s condition, and Dream Family solution for sleep therapy.

Amsterdam, the Netherlands – At a meeting with investors and financial analysts today in Amsterdam, Royal Philips (NYSE: PHG, AEX: PHIA) CEO Frans van Houten, together with CFO Abhijit Bhattacharya and several executives, will provide an update on the company’s performance and value creation journey.
“We are excited about the strong demand for our health technology innovations, and we will continue to drive our value creation journey, delivering mid-single-digit comparable sales growth and an annual improvement of the Adjusted EBITA margin of around 100 basis points,” said Frans van Houten. “To expand our market positions, increase margins and fully unlock Philips’ potential, we will further improve customer and operational excellence, boost growth in our core businesses through geographical expansion and consultative customer partnerships, and innovate with integrated solutions to improve people’s health and enhance the productivity of care providers.”

Innovation is core to Philips’ value creation, as exemplified by the company’s deep clinical partnerships and global EUR 1.8 billion R&D program. More than half of Philips’ annual sales is related to new product sales [3], such as Philips’ Azurion next-generation image-guided therapy platform, General Care Solution with Early Warning Scoring to identify subtle signs of deterioration in a general floor patient’s condition, and Dream Family solution for sleep therapy.

Amsterdam, the Netherlands – At a meeting with investors and financial analysts today in Amsterdam, Royal Philips (NYSE: PHG, AEX: PHIA) CEO Frans van Houten, together with CFO Abhijit Bhattacharya and several executives, will provide an update on the company’s performance and value creation journey.
“We are excited about the strong demand for our health technology innovations, and we will continue to drive our value creation journey, delivering mid-single-digit comparable sales growth and an annual improvement of the Adjusted EBITA margin of around 100 basis points,” said Frans van Houten. “To expand our market positions, increase margins and fully unlock Philips’ potential, we will further improve customer and operational excellence, boost growth in our core businesses through geographical expansion and consultative customer partnerships, and innovate with integrated solutions to improve people’s health and enhance the productivity of care providers.”

Innovation is core to Philips’ value creation, as exemplified by the company’s deep clinical partnerships and global EUR 1.8 billion R&D program. More than half of Philips’ annual sales is related to new product sales [3], such as Philips’ Azurion next-generation image-guided therapy platform, General Care Solution with Early Warning Scoring to identify subtle signs of deterioration in a general floor patient’s condition, and Dream Family solution for sleep therapy.

Amsterdam, the Netherlands – At a meeting with investors and financial analysts today in Amsterdam, Royal Philips (NYSE: PHG, AEX: PHIA) CEO Frans van Houten, together with CFO Abhijit Bhattacharya and several executives, will provide an update on the company’s performance and value creation journey.
“We are excited about the strong demand for our health technology innovations, and we will continue to drive our value creation journey, delivering mid-single-digit comparable sales growth and an annual improvement of the Adjusted EBITA margin of around 100 basis points,” said Frans van Houten. “To expand our market positions, increase margins and fully unlock Philips’ potential, we will further improve customer and operational excellence, boost growth in our core businesses through geographical expansion and consultative customer partnerships, and innovate with integrated solutions to improve people’s health and enhance the productivity of care providers.”

Innovation is core to Philips’ value creation, as exemplified by the company’s deep clinical partnerships and global EUR 1.8 billion R&D program. More than half of Philips’ annual sales is related to new product sales [3], such as Philips’ Azurion next-generation image-guided therapy platform, General Care Solution with Early Warning Scoring to identify subtle signs of deterioration in a general floor patient’s condition, and Dream Family solution for sleep therapy.

Amsterdam, the Netherlands – At a meeting with investors and financial analysts today in Amsterdam, Royal Philips (NYSE: PHG, AEX: PHIA) CEO Frans van Houten, together with CFO Abhijit Bhattacharya and several executives, will provide an update on the company’s performance and value creation journey.
“We are excited about the strong demand for our health technology innovations, and we will continue to drive our value creation journey, delivering mid-single-digit comparable sales growth and an annual improvement of the Adjusted EBITA margin of around 100 basis points,” said Frans van Houten. “To expand our market positions, increase margins and fully unlock Philips’ potential, we will further improve customer and operational excellence, boost growth in our core businesses through geographical expansion and consultative customer partnerships, and innovate with integrated solutions to improve people’s health and enhance the productivity of care providers.”

Innovation is core to Philips’ value creation, as exemplified by the company’s deep clinical partnerships and global EUR 1.8 billion R&D program. More than half of Philips’ annual sales is related to new product sales [3], such as Philips’ Azurion next-generation image-guided therapy platform, General Care Solution with Early Warning Scoring to identify subtle signs of deterioration in a general floor patient’s condition, and Dream Family solution for sleep therapy.

Amsterdam, the Netherlands – At a meeting with investors and financial analysts today in Amsterdam, Royal Philips (NYSE: PHG, AEX: PHIA) CEO Frans van Houten, together with CFO Abhijit Bhattacharya and several executives, will provide an update on the company’s performance and value creation journey.
“We are excited about the strong demand for our health technology innovations, and we will continue to drive our value creation journey, delivering mid-single-digit comparable sales growth and an annual improvement of the Adjusted EBITA margin of around 100 basis points,” said Frans van Houten. “To expand our market positions, increase margins and fully unlock Philips’ potential, we will further improve customer and operational excellence, boost growth in our core businesses through geographical expansion and consultative customer partnerships, and innovate with integrated solutions to improve people’s health and enhance the productivity of care providers.”

Innovation is core to Philips’ value creation, as exemplified by the company’s deep clinical partnerships and global EUR 1.8 billion R&D program. More than half of Philips’ annual sales is related to new product sales [3], such as Philips’ Azurion next-generation image-guided therapy platform, General Care Solution with Early Warning Scoring to identify subtle signs of deterioration in a general floor patient’s condition, and Dream Family solution for sleep therapy.

Amsterdam, the Netherlands – At a meeting with investors and financial analysts today in Amsterdam, Royal Philips (NYSE: PHG, AEX: PHIA) CEO Frans van Houten, together with CFO Abhijit Bhattacharya and several executives, will provide an update on the company’s performance and value creation journey.
“We are excited about the strong demand for our health technology innovations, and we will continue to drive our value creation journey, delivering mid-single-digit comparable sales growth and an annual improvement of the Adjusted EBITA margin of around 100 basis points,” said Frans van Houten. “To expand our market positions, increase margins and fully unlock Philips’ potential, we will further improve customer and operational excellence, boost growth in our core businesses through geographical expansion and consultative customer partnerships, and innovate with integrated solutions to improve people’s health and enhance the productivity of care providers.”

Innovation is core to Philips’ value creation, as exemplified by the company’s deep clinical partnerships and global EUR 1.8 billion R&D program. More than half of Philips’ annual sales is related to new product sales [3], such as Philips’ Azurion next-generation image-guided therapy platform, General Care Solution with Early Warning Scoring to identify subtle signs of deterioration in a general floor patient’s condition, and Dream Family solution for sleep therapy.

Amsterdam, the Netherlands – At a meeting with investors and financial analysts today in Amsterdam, Royal Philips (NYSE: PHG, AEX: PHIA) CEO Frans van Houten, together with CFO Abhijit Bhattacharya and several executives, will provide an update on the company’s performance and value creation journey.
“We are excited about the strong demand for our health technology innovations, and we will continue to drive our value creation journey, delivering mid-single-digit comparable sales growth and an annual improvement of the Adjusted EBITA margin of around 100 basis points,” said Frans van Houten. “To expand our market positions, increase margins and fully unlock Philips’ potential, we will further improve customer and operational excellence, boost growth in our core businesses through geographical expansion and consultative customer partnerships, and innovate with integrated solutions to improve people’s health and enhance the productivity of care providers.”

Innovation is core to Philips’ value creation, as exemplified by the company’s deep clinical partnerships and global EUR 1.8 billion R&D program. More than half of Philips’ annual sales is related to new product sales [3], such as Philips’ Azurion next-generation image-guided therapy platform, General Care Solution with Early Warning Scoring to identify subtle signs of deterioration in a general floor patient’s condition, and Dream Family solution for sleep therapy.

Amsterdam, the Netherlands – At a meeting with investors and financial analysts today in Amsterdam, Royal Philips (NYSE: PHG, AEX: PHIA) CEO Frans van Houten, together with CFO Abhijit Bhattacharya and several executives, will provide an update on the company’s performance and value creation journey.
“We are excited about the strong demand for our health technology innovations, and we will continue to drive our value creation journey, delivering mid-single-digit comparable sales growth and an annual improvement of the Adjusted EBITA margin of around 100 basis points,” said Frans van Houten. “To expand our market positions, increase margins and fully unlock Philips’ potential, we will further improve customer and operational excellence, boost growth in our core businesses through geographical expansion and consultative customer partnerships, and innovate with integrated solutions to improve people’s health and enhance the productivity of care providers.”

Innovation is core to Philips’ value creation, as exemplified by the company’s deep clinical partnerships and global EUR 1.8 billion R&D program. More than half of Philips’ annual sales is related to new product sales [3], such as Philips’ Azurion next-generation image-guided therapy platform, General Care Solution with Early Warning Scoring to identify subtle signs of deterioration in a general floor patient’s condition, and Dream Family solution for sleep therapy.

Amsterdam, the Netherlands – At a meeting with investors and financial analysts today in Amsterdam, Royal Philips (NYSE: PHG, AEX: PHIA) CEO Frans van Houten, together with CFO Abhijit Bhattacharya and several executives, will provide an update on the company’s performance and value creation journey.
“We are excited about the strong demand for our health technology innovations, and we will continue to drive our value creation journey, delivering mid-single-digit comparable sales growth and an annual improvement of the Adjusted EBITA margin of around 100 basis points,” said Frans van Houten. “To expand our market positions, increase margins and fully unlock Philips’ potential, we will further improve customer and operational excellence, boost growth in our core businesses through geographical expansion and consultative customer partnerships, and innovate with integrated solutions to improve people’s health and enhance the productivity of care providers.”

Innovation is core to Philips’ value creation, as exemplified by the company’s deep clinical partnerships and global EUR 1.8 billion R&D program. More than half of Philips’ annual sales is related to new product sales [3], such as Philips’ Azurion next-generation image-guided therapy platform, General Care Solution with Early Warning Scoring to identify subtle signs of deterioration in a general floor patient’s condition, and Dream Family solution for sleep therapy.